Cataract Clinical Trial
Official title:
Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema
This study is undertaken to determine the effect of intravitreal long acting dexamethasone
implant, (Ozurdex®) in improving outcome of cataract surgery in patients with diabetic
macular edema.
Diabetic Macular Edema and cataract constitute important causes of visual impairment in
patients with diabetes. Cataract surgery in patients with diabetic retinopathy is associated
with progression of retinopathy.
Several modalities such as non-steroidal anti-inflammatory agents, carbonic anhydrase
inhibitors, corticosteroids, hyperbaric oxygen, laser photocoagulation and vitrectomy with
internal limiting membrane peeling have been tried for managing inflammatory cystoid macular
edema.
Intravitreal Triamcinolone Acetonide (TA), a water insoluble steroid, has been shown to
reduce the retinal thickness and improve the visual acuity. However, recurrence of macular
edema in patients who receive intravitreal TA is a major concern as the patients need
multiple repeat injections.
In search for the ideal corticosteroid preparation, a Dexamethasone Posterior Segment Drug
Delivery System (Dexamethasone DDS - Ozurdex®, Allergan Inc, Irvine, California) was
recently developed. Promising results have been shown in certain patients with persistent
diabetic macular edema receiving this intravitreal drug delivery system with improvement in
visual acuity
The present study introduces a novel concept of using intraoperative Ozurdex ® implant in
patients with diabetes mellitus while undergoing cataract surgery to minimize the worsening
of diabetic maculopathy.
Diabetic Macular Edema (DME) and cataract constitute important causes of visual impairment
in patients with diabetes mellitus. Cataract surgery in patients with diabetic retinopathy
is associated with progression of both retinopathy and maculopathy in nearly 23-57% of
cases, thus affecting the final visual outcome. Post-cataract surgery, macular edema may be
due to worsening/presence of pre-existing clinically significant macular edema (CSME) or due
to development of Irvine Gass Syndrome where cystoid macular edema (CME) occurs in the post
operative period and is believed to be inflammatory in origin. Focal/ grid laser
photocoagulation is the standard of care in the management of CSME, which may be
pre-existing at the time of cataract surgery or worsens following surgery. Several adjuncts
including intravitreal corticosteroids, Pegaptanib Sodium (Macugen; Pfizer, New York),
Ranibizumab (Lucentis; Genentech, South San Francisco, California), Bevacizumab (Avastin,
Genentech) have been tried in an attempt to improve the visual results.
Several modalities such as non-steroidal anti-inflammatory agents, carbonic anhydrase
inhibitors, corticosteroids, hyperbaric oxygen, laser photocoagulation and vitrectomy with
internal limiting membrane peeling have been tried for managing inflammatory cystoid macular
edema13. Intravitreal Triamcinolone Acetonide (TA), a water insoluble steroid, has been
shown to reduce the retinal thickness and improve the visual acuity14-16. However,
recurrence of macular edema in patients who receive intravitreal TA is a major concern as
the patients need multiple repeat injections because of the short half life of the drug
(18.6 days). A more potent steroid, dexamethasone has also been tried as an alternative to
TA for macular edema; however, its short half life of only 3 hours prevents its clinical
application.
In search for the ideal corticosteroid preparation, a Dexamethasone Posterior Segment Drug
Delivery System (DDS) - Ozurdex®, Allergan Inc, Irvine, California) was recently developed
which has generated new interest in this molecule. It is a sustained release intravitreal
implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug
Administration) for treatment of macular edema in retinal vein occlusions. Promising results
have been shown in certain patients with persistent diabetic macular edema receiving this
intravitreal drug delivery system with improvement in visual acuity.
The present study introduces a novel concept of using intraoperative Ozurdex ® implant in
patients with diabetes mellitus while undergoing cataract surgery to minimize the worsening
of diabetic maculopathy.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |